A dated view of newly published profiles, Human Evidence Reviews, study context, official-source notes, and source records. Each entry links to the exact public context that changed.
Site addition is when this published item entered the collection. A source date belongs to the cited registry, publication, label, or agency record. A review date identifies the human or editorial reading of a source set. Source checked is the recorded retrieval or verification date. A recent addition or registry check does not by itself change a review conclusion.
This page contains published records only. It does not claim exhaustive source monitoring or provide treatment advice.
Newest first
Published changes
Through November 17, 2026
Showing the newest 100 of 5,571 published changes. Every source record remains available in the evidence archive and the latest ones at /updates/; this mixed view keeps each evidence type distinct.
PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.
PubMed lists PMID 43041099 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2027-01 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 203857 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206873 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206936 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for BLA 021839 with status AP dated 2005-08-30, and names mecasermin recombinant among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 018123 with status AP dated 1982-09-30, and names gonadorelin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 020622 with status AP dated 1996-12-20, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 208547 with status AP dated 2016-06-01, and names gallium dotatate ga-68 among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients.
The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.
The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.
The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.
The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.
The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.
The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.
The Federal Register published notice 2016-08682, attributed to FDA and its parent HHS department, on 2016-04-15. Its official title is “Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.
The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner's exact reviewed identity mapping connects the document to Albiglutide.
The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.
The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.
The Federal Register published notice 2018-15735, attributed to FDA and its parent HHS department, on 2018-07-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.
The Federal Register published notice 2019-02146, attributed to FDA and its parent HHS department, on 2019-02-13. Its official title is “Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.
The Federal Register published notice 2019-09007, attributed to FDA and its parent HHS department, on 2019-05-03. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.
The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.
The Federal Register published notice 97-10541, attributed to FDA and its parent HHS department, on 1997-04-23. Its official title is “Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.
The Federal Register published notice 98-7053, attributed to FDA and its parent HHS department, on 1998-03-19. Its official title is “Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.
The Federal Register published notice E6-12571, attributed to FDA and its parent HHS department, on 2006-08-03. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; IPLEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.
The Federal Register published notice E6-9138, attributed to FDA and its parent HHS department, on 2006-06-13. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; INCRELEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.
The Federal Register published proposed rule 2015-32246, attributed to FDA and its parent HHS department, on 2015-12-23. Its official title is “Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.
PubMed lists PMID 43030876 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Update: We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not.
A long-acting insulin glargine product licensed by FDA as Langlara in April 2026 to improve blood-sugar control in adults and children with diabetes.
Update: We added the FDA labels of Sandostatin LAR and Mycapssa and now describe each trial with the octreotide product it tested, because the generic label cited on this page has no clinical studies section.
A somatostatin analogue first approved by FDA as Sandostatin in 1988, used for acromegaly and for diarrhea and flushing caused by certain hormone-secreting tumors.
Update: We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials.
An experimental amylin analogue from Zealand Pharma and Roche, in Phase 3 trials. It is not FDA-approved.
Update: We added FDA’s May 2026 503A nominations list, which places GHRP-2 in category 3, and two human studies of its effect on growth hormone and appetite and its use as a diagnostic test.
A synthetic six-amino-acid growth hormone secretagogue, also called pralmorelin, that FDA lists among compounding substances that may present significant safety risks.
Update: We added three randomized trials of LL-37 in chronic ulcers, FDA’s advisory committee page listing LL-37 for a meeting before the end of February 2027, and the spelling LL37 that trial registrations use, so that those registrations are matched.
A 37-amino-acid human cathelicidin peptide, also called ropocamptide, tested in small trials in chronic ulcers. FDA lists it among compounding substances that may present significant safety risks.
Update: We added two early human studies of Melanotan II and FDA’s advisory committee page listing it for a meeting before the end of February 2027.
A synthetic cyclic seven-unit peptide that FDA lists among compounding substances that may present significant safety risks, citing case reports of serious adverse events.
Update: We added a 2015 Russian clinical study of selank added to phenazepam in patients with anxiety disorders. Earlier versions said no human study was cited among the sources reviewed.
A synthetic seven-amino-acid peptide that FDA lists among withdrawn compounding nominations with possible safety risks. FDA states that it lacks important information on its safety in people.
A small synthetic compound, not a peptide, that blocks the enzyme NNMT. A 2018 study found that obese mice given it lost weight; no human studies are reported.
A GLP-1 receptor agonist made by fusing GLP-1 analogue peptides to human albumin. FDA approved it as Tanzeum in 2014, and Drugs@FDA lists it as discontinued.
A mixture of small peptides and amino acids from pig brain, used for stroke in several countries. A 2023 Cochrane review found it probably does not reduce deaths, and no FDA approval is reported.
A lipoglycopeptide antibiotic approved by FDA in 2014 as Dalvance for acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including MRSA.
A lab-made, stabilized fragment of the hormone angiotensin IV, designed as a possible dementia drug and tested in rats. FDA has identified no human exposure data, and no FDA approval is reported.
An experimental GLP-1 and glucagon receptor agonist studied for fatty liver disease. In a 24-week trial it reduced liver fat more than semaglutide; no FDA approval is reported.
A GLP-1 receptor agonist made by joining an exendin-4 analogue to an antibody fragment. A 4,076-person trial found fewer cardiovascular events than placebo; no FDA approval is reported.
A form of follistatin, a natural protein, not a peptide, that blocks the muscle-limiting signal myostatin. Small gene-therapy trials have tested its gene; no FDA approval is reported.
A lab-designed peptide that makes ageing (senescent) cells die by blocking FOXO4 from holding p53. It restored some functions in old mice; no human studies and no FDA approval are reported.
A radioactive imaging agent built on dotatate, a cyclic eight-amino-acid peptide. FDA approved the NETSPOT kit in 2016 for PET scans that locate somatostatin receptor-positive neuroendocrine tumors.
A mixture of synthetic polypeptides made from four amino acids, not a single peptide. FDA approved it as Copaxone in 1996 for relapsing forms of multiple sclerosis.
The synthetic form of gonadotropin-releasing hormone. FDA approved it as Factrel in 1982 and Lutrepulse in 1989, and Drugs@FDA lists both as discontinued.
A 24-amino-acid peptide identified in 2001 as protecting nerve cells from Alzheimer disease-related damage in the laboratory. No human studies and no FDA approval are reported.
An engineered, 83-amino-acid form of the growth factor IGF-1, a protein, not a peptide, made as a laboratory research tool. No human studies and no FDA approval are reported.
Recombinant human IGF-1, a 70-amino-acid protein, not a peptide, approved by FDA in 2005 as Increlex to treat growth failure in children with severe primary IGF-1 deficiency.
A recombinant form of the hormone leptin, a 147-amino-acid protein, not a peptide, approved by FDA in 2014 as Myalept for complications of leptin deficiency in generalized lipodystrophy.
A small synthetic compound, not a peptide, also called ibutamoren, that prompts growth hormone release. FDA lists it among compounding substances that may present significant safety risks, citing congestive heart failure.
A small-molecule GLP-1 receptor agonist, not a peptide, approved by FDA in April 2026 as Foundayo for weight reduction in adults with obesity or overweight with a related condition.
A pegylated form of mechano growth factor, a synthetic 24-amino-acid peptide based on the insulin-like growth factor 1 precursor. FDA has identified no human exposure data, and no FDA approval is reported.
A synthetic peptide-based drug for anemia in kidney disease, approved by FDA as Omontys in 2012. It was recalled in 2013 after fatal allergic reactions, and FDA withdrew its approval in 2019 at the company’s request.
A small synthetic compound, not a peptide, that activates estrogen-related receptors and acted like exercise in mice. No human studies and no FDA approval are reported.
A small synthetic drug, not a peptide, that blocks the reuptake of noradrenaline, dopamine and serotonin. It was studied in phase 2 trials for obesity and Parkinson disease, and no FDA approval is reported.
A synthetic five-amino-acid fragment of thymopoietin, studied as an immune modulator. Randomized trials in the 1990s had mixed results, and no FDA approval is reported.
An experimental GLP-1 and GIP receptor dual agonist studied for weight management. In a 13-week phase 2 trial, average weight loss was 9.1% to 14.7%; no FDA approval is reported.
Update: PubMed revised the bibliographic metadata of PMID 42713641, with a metadata revision date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed lists PMID 42713641 in NEJM evidence as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Update: ClinicalTrials.gov posted a newer version of NCT04775082, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide.
Update: ClinicalTrials.gov posted a newer version of NCT05278208, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
Update: ClinicalTrials.gov posted a newer version of NCT05669664, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide.
Update: ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide.
Update: ClinicalTrials.gov posted a newer version of NCT07220759, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide.
Update: ClinicalTrials.gov posted a newer version of NCT07843472, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide.
Update: PubMed revised the bibliographic metadata of PMID 42709517, with a metadata revision date of 2026-10-30. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Update: PubMed revised the bibliographic metadata of PMID 42270043, with a metadata revision date of 2026-10-28. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Update: PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Update: PubMed revised the bibliographic metadata of PMID 42400596, with a metadata revision date of 2026-11-04. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, Comparative Study, with publication-date metadata of 2026-11-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Update: PubMed revised the bibliographic metadata of PMID 42469146, with a metadata revision date of 2026-11-03. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.